Skip to main content

ASCPT 2025 Annual Meeting Main banner

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

C
LB-019
CAN PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING COMPLEMENT THERAPEUTIC DRUG MONITORING FOR DIGOXIN DOSE OPTIMIZATION IN PATIENTS WITH RENAL IMPAIRMENT?

Favorite
LB-022
CAN THE POTENTIAL OF A DRUG TO INHIBIT URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE (UGT) ENZYMES BE PREDICTED? INSIGHTS FROM A RETROSPECTIVE ANALYSIS.

Favorite
LB-022
CAN THE POTENTIAL OF A DRUG TO INHIBIT URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE (UGT) ENZYMES BE PREDICTED? INSIGHTS FROM A RETROSPECTIVE ANALYSIS.

Favorite
PI-059
CASDATIFAN (AB521) PHARMACOKINETICS IS SIMILAR WHEN ADMINISTERED AS CAPSULES OR TABLETS AND IS UNAFFECTED BY FOOD

Favorite
PII-060
CHALLENGES IN PREDICTING PEDIATRIC DRUG EXPOSURE WITH ALLOMETRIC SCALING: IMPLICATIONS FOR OPTIMIZING PEDIATRIC TRIAL DESIGNS

Favorite
PII-016
CHARACTERIZATION AND PHARMACOKINETIC MODELLING OF VANCOMYCIN IN CRITICALLY ILL ICU PATIENTS UNDERGOING CVVHD

Favorite
PI-060
CHARACTERIZING COLISTIN PHARMACOKINETICS FOLLOWING A LOADING DOSE: FIRST DESCRIPTION IN AN AFRICAN COHORT.

Favorite
PII-024
CHARACTERIZING METHADONE:METABOLITE RATIO DURING METHADONE INDUCTION IN PREGNANCY

Favorite
PII-027
CHARACTERIZING NETUPITANT'S FUNCTION AS AN NADK2 INHIBITOR: IMPACT ON CELL VIABILITY AND METABOLISM.

Favorite
PII-011
CHARACTERIZING QTC PROLONGATION RISK FROM CONCOMITANT MEDICATIONS IN PATIENTS WITH BREAST CANCER AMONG PHARMETRICS PLUS.

Favorite
LB-006
CLINICAL AND ETHICAL PERSPECTIVES ON THE EMERGING ROLE OF PHARMACOGENOMIC TESTING AMONG MENTAL HEALTH PROVIDERS: A QUALITATIVE EXAMINATION

Favorite
PII-022
CLINICAL DRUG-DRUG INTERACTION STUDIES INVESTIGATING THE EFFECT OF BAY 2927088 ON P-GP AND BCRP USING DABIGATRAN ETEXILATE AND ROSUVASTATIN

Favorite
PII-061
CLINICAL DRUG-DRUG INTERACTION STUDIES THROUGH CYTOCHROME P450 3A (CYP3A) AND P-GLYCOPROTEIN (P-GP) FOR BAY 2927088 USING ITRACONAZOLE (ITZ), CARBAMAZEPINE (CBZ) AND MIDAZOLAM (MDZ)

Favorite
PI-028
CLINICAL PHARMACOKINETICS AND BIOMARKER ANALYSES OF RC88, A NEW MESOTHELIN-TARGETING ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS

Favorite
PII-107
CLINICAL STUDY TO INVESTIGATE THE EFFECT OF ADMINISTRATION OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND AN OPIOID ON VENTILATION.

Favorite
PI-061
CLOFAZIMINE PHARMACOKINETICS FOR MULTIDRUG-RESISTANT TB: IMPLICATION OF NOVEL COMBINATION REGIMENS.

Favorite
PII-028
CLONAL HEMATOPOIESIS AS A PRECISION MEDICINE BIOMARKER FOR PATIENTS WITH CANCER

Favorite
PII-003
COMPLIANCE, USABILITY, RELIABILITY, AND CONSTRUCT VALIDITY OF SELF-ADMINISTERED DIGITAL MEASURES DERIVED FROM MDS-UPDRS PARTS 2 AND 3 IN AN OBSERVATIONAL STUDY TO EVALUATE PARKINSON'S DISEASE (PD) PROGRESSION: INTERIM ANALYSIS.

Favorite
PII-062
COMPREHENSIVE PHARMACOKINETIC ANALYSIS OF ISONIAZID IN A LARGE COHORT OF TUBERCULOSIS PATIENTS: ADVANCED MODELING INCORPORATING EXTENSIVE CLINICAL COVARIATES.

Favorite
PI-012
CONCENTRATION-QT ANALYSIS FOR BAY 2927088 INDICATES NO CLINICALLY RELEVANT QTC INTERVAL PROLONGATION

Favorite
PI-062
CONCENTRATION-QTC ANALYSIS OF PATRITUMAB DERUXTECAN IN PATIENTS WITH HER3-EXPRESSING METASTATIC BREAST CANCER OR METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER

Favorite
PI-017
CONCENTRATION-RESPONSE RELATIONSHIP OF MAM01, AN INVESTIGATIONAL MONOCLONAL ANTIBODY TARGETING THE CIRCUMSPOROZOITE PROTEIN (CSP), IN A CONTROLLED HUMAN INFECTION MODEL (CHIM) STUDY.

Favorite
PII-012
CONSIDERATIONS FOR PHASE 1 CLINICAL TRIALS IN ADULT PATIENTS

Favorite
PI-013
CONSIDERATIONS ON HUMAN ADME STUDIES AND PROPOSED DECISION TREE TOWARDS TAILORED STUDY DESIGNS.

Favorite
PWII-005
CONSTRUCTING EXTERNAL CONTROL (EC) ARMS FOR ORGAN IMPAIRMENT (OI) STUDIES: COMPARING STATISTICAL MATCHING AND POOLING METHODS

Favorite
PT-020
CONSTRUCTING EXTERNAL CONTROL (EC) ARMS FOR ORGAN IMPAIRMENT (OI) STUDIES: COMPARING STATISTICAL MATCHING AND POOLING METHODS

Favorite
PII-063
COST EFFECTIVENESS OF INDIVIDUALIZED DOSING FOR A HYPOTHETICAL NEW DRUG IN ATOPIC DERMATITIS: A PHARMACOMETRIC-PHARMACOECONOMIC SIMULATION STUDY.

Favorite
LB-004
COUPLING BIOMARKER KNOWLEDGE WITH THE STRENGTHS OF PHARMACOMETRICS AND MACHINE LEARNING FOR INDIVIDUAL PROGNOSIS IN ONCOLOGY: A PRECISION MEDICINE FRAMEWORK FOR HEALTH CARE PROVIDERS

Favorite
E-006
CXCR4 ANTAGONISM CORRECTS PERIPHERAL NEUTROPENIA IN A MOUSE MODEL OF WHIM SYNDROME.

Favorite